MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Seres Therapeutics Company Profile (NASDAQ:MCRB)

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $43.86 (46.14% upside)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2016FBR & Co.Reiterated RatingOutperform$40.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016GuggenheimInitiated CoverageBuy$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016HC WainwrightReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Leerink SwannLower Price TargetOutperform$60.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$35.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2015Bank of AmericaUpgradeNeutral -> Buy$41.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha